🇺🇸 FDA
Pipeline program

Dexmedetomidine

IRB-XWAD-202008-12

Approved small_molecule completed

Quick answer

Dexmedetomidine for Lower Limb Fracture is a Approved program (small_molecule) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
China SXT Pharmaceuticals
Indication
Lower Limb Fracture
Phase
Approved
Modality
small_molecule
Status
completed

Clinical trials